Immune Modulation, Inc. (IMI) is a natural products-based biotech company. One such product, hypoestoxide (HE), is the lead product. HE is presently at the end of the pre-clinical testing phase. Completion of this phase will enable IMI to apply to the FDA to conduct clinical trials against Parkinson's disease (PD). There is no effective drug for PD in the market. HE will make our company special for being the first effective drug for PD.